Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00451859 | Breast | Precancer | maintenance of protein location | 19/1080 | 94/18723 | 1.43e-06 | 5.35e-05 | 19 |
GO:00512358 | Breast | Precancer | maintenance of location | 40/1080 | 327/18723 | 5.85e-06 | 1.71e-04 | 40 |
GO:00353049 | Breast | Precancer | regulation of protein dephosphorylation | 14/1080 | 90/18723 | 6.16e-04 | 7.72e-03 | 14 |
GO:00066059 | Breast | Precancer | protein targeting | 33/1080 | 314/18723 | 6.50e-04 | 7.99e-03 | 33 |
GO:00353086 | Breast | Precancer | negative regulation of protein dephosphorylation | 7/1080 | 34/18723 | 2.84e-03 | 2.49e-02 | 7 |
GO:00512203 | Breast | Precancer | cytoplasmic sequestering of protein | 5/1080 | 22/18723 | 7.32e-03 | 4.88e-02 | 5 |
GO:004518514 | Breast | IDC | maintenance of protein location | 21/1434 | 94/18723 | 6.69e-06 | 2.05e-04 | 21 |
GO:005123513 | Breast | IDC | maintenance of location | 48/1434 | 327/18723 | 9.90e-06 | 2.77e-04 | 48 |
GO:003530414 | Breast | IDC | regulation of protein dephosphorylation | 18/1434 | 90/18723 | 1.39e-04 | 2.48e-03 | 18 |
GO:000660514 | Breast | IDC | protein targeting | 43/1434 | 314/18723 | 1.44e-04 | 2.53e-03 | 43 |
GO:00459369 | Breast | IDC | negative regulation of phosphate metabolic process | 53/1434 | 441/18723 | 7.21e-04 | 8.79e-03 | 53 |
GO:00105639 | Breast | IDC | negative regulation of phosphorus metabolic process | 53/1434 | 442/18723 | 7.60e-04 | 9.25e-03 | 53 |
GO:003530813 | Breast | IDC | negative regulation of protein dephosphorylation | 9/1434 | 34/18723 | 8.01e-04 | 9.58e-03 | 9 |
GO:00353052 | Breast | IDC | negative regulation of dephosphorylation | 9/1434 | 45/18723 | 6.33e-03 | 4.47e-02 | 9 |
GO:004518521 | Breast | DCIS | maintenance of protein location | 21/1390 | 94/18723 | 4.12e-06 | 1.24e-04 | 21 |
GO:005123523 | Breast | DCIS | maintenance of location | 47/1390 | 327/18723 | 9.55e-06 | 2.56e-04 | 47 |
GO:000660523 | Breast | DCIS | protein targeting | 43/1390 | 314/18723 | 7.17e-05 | 1.41e-03 | 43 |
GO:003530423 | Breast | DCIS | regulation of protein dephosphorylation | 18/1390 | 90/18723 | 9.33e-05 | 1.71e-03 | 18 |
GO:004593614 | Breast | DCIS | negative regulation of phosphate metabolic process | 53/1390 | 441/18723 | 3.48e-04 | 4.96e-03 | 53 |
GO:001056314 | Breast | DCIS | negative regulation of phosphorus metabolic process | 53/1390 | 442/18723 | 3.68e-04 | 5.18e-03 | 53 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
YWHAB | SNV | Missense_Mutation | | c.724G>T | p.Gly242Trp | p.G242W | P31946 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.664) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
YWHAB | SNV | Missense_Mutation | novel | c.505N>T | p.Arg169Cys | p.R169C | P31946 | protein_coding | tolerated_low_confidence(0.07) | probably_damaging(0.937) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
YWHAB | SNV | Missense_Mutation | | c.184N>T | p.Arg62Cys | p.R62C | P31946 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.999) | TCGA-D8-A142-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamid | SD |
YWHAB | SNV | Missense_Mutation | novel | c.121G>A | p.Glu41Lys | p.E41K | P31946 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.992) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
YWHAB | SNV | Missense_Mutation | novel | c.460N>T | p.Ala154Ser | p.A154S | P31946 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.99) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
YWHAB | SNV | Missense_Mutation | rs374058745 | c.620C>T | p.Thr207Met | p.T207M | P31946 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.898) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
YWHAB | SNV | Missense_Mutation | novel | c.505C>T | p.Arg169Cys | p.R169C | P31946 | protein_coding | tolerated_low_confidence(0.07) | probably_damaging(0.937) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
YWHAB | SNV | Missense_Mutation | rs11556823 | c.173G>A | p.Arg58His | p.R58H | P31946 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.996) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
YWHAB | SNV | Missense_Mutation | novel | c.505N>T | p.Arg169Cys | p.R169C | P31946 | protein_coding | tolerated_low_confidence(0.07) | probably_damaging(0.937) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
YWHAB | SNV | Missense_Mutation | novel | c.595N>A | p.Asp199Asn | p.D199N | P31946 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.534) | TCGA-DI-A1NO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |